1. Home
  2. ENTA vs ALTI Comparison

ENTA vs ALTI Comparison

Compare ENTA & ALTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$12.51

Market Cap

374.6M

Sector

Health Care

ML Signal

HOLD

Logo AlTi Global Inc.

ALTI

AlTi Global Inc.

HOLD

Current Price

$3.42

Market Cap

394.0M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTA
ALTI
Founded
1995
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
374.6M
394.0M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
ENTA
ALTI
Price
$12.51
$3.42
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$20.40
N/A
AVG Volume (30 Days)
147.1K
138.5K
Earning Date
05-11-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
29.93
41.11
EPS
N/A
N/A
Revenue
$102,814,000.00
$206,935,000.00
Revenue This Year
$7.76
$25.64
Revenue Next Year
N/A
$15.77
P/E Ratio
N/A
N/A
Revenue Growth
16.48
N/A
52 Week Low
$4.09
$2.62
52 Week High
$17.15
$5.45

Technical Indicators

Market Signals
Indicator
ENTA
ALTI
Relative Strength Index (RSI) 40.96 33.20
Support Level $12.09 $3.31
Resistance Level $15.52 $4.12
Average True Range (ATR) 0.65 0.28
MACD -0.16 -0.05
Stochastic Oscillator 15.25 34.81

Price Performance

Historical Comparison
ENTA
ALTI

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About ALTI AlTi Global Inc.

AlTi Global Inc is an independent wealth and asset manager providing entrepreneurs, multi-generational families, institutions, and emerging next-generation leaders with fiduciary capabilities as well as alternative investment strategies and advisory services. The firm has business which is organized into two business segments namely: Wealth & Capital Solutions and the International Real Estate segment includes providing holistic solutions for wealth management clients through comprehensive range of wealth management services, including investment management and advisory services. International Real Estate segment includes assist investors with real estate co-investments, structuring and selecting partners with a track record with risk adjusted return characteristics.

Share on Social Networks: